Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Stopped early · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with progressive glioblastoma multiforme.

Key facts

Study ID

NCT00227032

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

10

Starts

2005-09-01

Expected to finish

2008-03-01

Last updated by the study team

2012-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.